Lucid Diagnostics Inc (NASDAQ:LUCD) price on current trading day, rose 15.41% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.53.
A look at the stock’s price movement, the level at last check in today’s session was $1.33. Turning to its 52-week performance, $1.80 and $0.68 were the 52-week high and 52-week low respectively. Overall, LUCD moved 15.41% over the past month.
Lucid Diagnostics Inc’s market cap currently stands at around $166.07 million, with investors looking forward to this quarter’s earnings report slated for in June.
Analysts have a consensus estimate of 1.23M for the company’s revenue for the quarter, with a low and high estimate of 1M and 1.45M respectively. The average forecast suggests up to a 25.87% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 6.71M, representing a 54.43% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LUCD is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend LUCD as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LUCD’s current price about 21.97% and 13.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 68.04, while 7-day volatility ratio is 1.60% and 3.51% in the 30-day chart. Further, Lucid Diagnostics Inc (LUCD) has a beta value of 1.29, and an average true range (ATR) of 0.10. Analysts have given the company’s stock an average 52-week price target of $2, forecast between a low of $2 and high of $2. Looking at the price targets, the low is -30.72% off recent price level in today’s trading while to achieve the yearly target high, it has to move -30.72%. Nonetheless, investors will most likely welcome a -30.72% jump to $2 which is the analysts’ median price.
If we refocus on Lucid Diagnostics Inc (NASDAQ:LUCD), historical trading data shows that trading volumes averaged 1.08 million over the past 3 months. The company’s latest data on shares outstanding shows there are 84.37 million shares.
The 62.03% of Lucid Diagnostics Inc’s shares are in the hands of company insiders while institutional holders own 9.78% of the company’s shares. Current price change has pushed the stock 87.49% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LUCD stock continues to rise going into the next quarter.
